Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

STAT-Diagnostica Appoints Board Chairman

Published: Thursday, June 20, 2013
Last Updated: Thursday, June 20, 2013
Bookmark and Share
Company names Gérard Vaillant as chairman of the company’s board of directors.

STAT-Diagnostica has appointed Gérard Vaillant as chairman of the company’s board of directors. With more than three decades of senior leadership experience in the medical device and diagnostics sector, he brings expert industry perspective and guidance to the company as it prepares for the successive European and U.S. launches of its novel DiagCORE Near Patient Testing platform.

Vaillant is a career veteran of Johnson & Johnson Worldwide who has held of number of senior executive positions within the organization.

These include managing director, Ortho Clinical Diagnostics France (1981 - 1987); vice president, Johnson & Johnson International (1987 - 1992); worldwide president, LifeScan, a Johnson & Johnson company (1992 - 1995); and company group chairman, Diagnostics Worldwide (1995 - 2004).

He was also a member of Johnson & Johnson’s Medical Devices and Diagnostic Group Operating Committee until retiring in 2004.

After his retirement from Johnson & Johnson, he remained active in the industry as board member of both Luminex and Vivacta.

In addition to his current position with STAT-Diagnostica, Vaillant currently serves as chairman of the board of SafeOrthopaedics and PathoQuest; board member of Tecan CH; and venture partner at KLS Partners.

“We are very privileged to have Gérard join as the chairman of our board of directors,” said Jordi Carrerra, CEO and co-founder of STAT-Diagnostica.

Carrerra continued, “His deep industry pedigree and proven track record of success will be invaluable to us as we move towards European and U.S. approval and commercialization of our DiagCORE platform.”

Vaillant joins STAT-Diagnostica following the company’s closing of a Series B financing round totaling $22.1 million/17 million Euros, which was announced May 6, 2013.

Led by new investor Kurma Life Sciences Partners, the round also drew participation from new investors Idinvest; Boehringer Ingelheim Venture Fund; and, Caixa Capital Risc, the venture capital division of “la Caixa;” as well as existing investors Ysios Capital and Axis.

The proceeds of the funding are being used to complete development of the company’s DiagCORE platform and clinical validation of its first products.

“The DiagCORE platform represents a significant breakthrough in the area of Near Patient Testing that stands to change clinical practice in the critical care setting,” said Vaillant.

Vaillant continued, “In addition to its unique technology, STAT-Diagnostica’s excellent leadership and strong investor support are what attracted me to the board chairman position. I look forward to being part of the company’s future success.”

STAT-Diagnostica’s DiagCORE Near Patient Testing platform is designed to simplify and reduce time to results for the diagnosis of certain medical conditions.

The in vitro diagnostic system is a versatile, easy-to-use platform that consolidates molecular and immunoassay techniques in a single device.

The first clinical applications will be directed at infectious disease detection, antibiotic resistance determination and detection of biomarkers in critically ill patients.

STAT-Diagnostica’s DiagCORE platform not only offers multi-analyte and multi-sample capabilities, but it also reduces current diagnosis times (which can take up to several days) by providing results in less than 30 minutes.

The system’s rapid performance will enable improved clinical decision making by medical practitioners, delivering better patient management with direct and indirect savings to the healthcare system.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Head Injury Patients have Protein Clumps Associated with Alzheimer’s Disease
Scientists have revealed that protein clumps associated with Alzheimer's disease are also found in the brains of people who have had a head injury.
Exposure to Air Pollution 30 Years Ago Associated with Increased Risk of Death
Exposure to air pollution more than 30 years ago may still affect an individual's mortality risk today, according to new research from Imperial College London.
More Then 1 in 20 U.S. Children have Dizziness and Balance Problems
Researchers at NIH have found that girls have a higher prevalence of dizziness and balance problems compared to boys, 5.7 percent and 5.0 percent.
Biosensors on Demand
New strategy results in custom "designer proteins" for sensing a variety of molecules.
Low-Cost, Portable NQR Spectroscopy
A researcher at Case Western Reserve University is developing a low-cost, portable prototype designed to detect tainted medicines and food supplements that otherwise can make their way to consumers. The technology can authenticate good medicines and supplements.
Structure of Brain Plaques in Huntington's
Researchers at the University of Pittsburgh School of Medicine have shown that the core of the protein clumps found in the brains of people with Huntington's disease have a distinctive structure, a finding that could shed light on the molecular mechanisms underlying the neurodegenerative disorder.
Insights into the Function of the Main Class of Drug Targets
About thirty percent of all medical drugs such as beta-blockers or antidepressants interact with certain types of cell surface proteins called G protein coupled receptors.
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Unique Mechanism for a High-Risk Leukemia
Researchers uncovered the aberrant mechanism underlying a notoriously treatment-resistant acute lymphoblastic leukemia subtype; findings offer lessons for understanding all cancers.
Visualizing a Cancer Drug Target at Atomic Resolution
Using cryo-electron microscopy, researchers were able to view, in atomic detail, the binding of a potential small molecule drug to a key protein in cancer cells.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!